Advances in Management for Older Adults With Hematologic Malignancies
Authors: Ashley E. Rosko, Raul Cordoba, Gregory Abel, Andrew Artz, Kah Poh Loh, Heidi D. Klepin
Journal: Journal of Clinical Oncology (2021)

Article Tools REVIEW ARTICLES Caring for Older Adults With Cancer Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.21.00242 Journal of Clinical Oncology - published online before print May 27, 2021 PMID: 34043442 Advances in Management for Older Adults With Hematologic Malignancies Ashley E. Rosko , MD1xAshley E. RoskoSearch for articles by this author; Raul Cordoba , MD, PhD2xRaul CordobaSearch for articles by this author; Gregory Abel , MD, MPH3xGregory AbelSearch for articles by this author; Andrew Artz , MD4xAndrew ArtzSearch for articles by this author; Kah Poh Loh , MBBCh, BAO5xKah Poh LohSearch for articles by this author; and Heidi D. Klepin , MD, MS6xHeidi D. KlepinSearch for articles by this author Show More 1Division of Hematology, The Ohio State University, Columbus, OH2Lymphoma Unit, Department of Hematology, Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain3Leukemia Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA4Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA5James P. Wilmot Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY6Section on Hematology and Oncology, Wake Forest Baptist Health, Winston-Salem, NC https://doi.org/10.1200/JCO.21.00242 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveHow do advances in therapeutics and geriatric assessment (GA) strategies inform personalized management for older adults with hematologic malignancies?Knowledge GeneratedNovel therapeutics, targeted therapies, and maintenance strategies are improving outcomes for older adults including those who have functional impairments and competing comorbid conditions. GA and frailty measures are predictive of treatment tolerance and outcomes across various hematologic malignancies.RelevanceIntegration of GA measures into practice can inform shared treatment decisions and guide management of identified vulnerabilities to enhance therapeutic benefit and quality of life.SUPPORTH.D.K. was supported by the National Institute on Aging (R33AG059206).AUTHOR CONTRIBUTIONSConception and design: Ashley E. Rosko, Raul Cordoba, Gregory Abel, Andrew Artz, Heidi D. KlepinProvision of study materials or patients: Kah Poh LohCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTAdvances in Management for Older Adults With Hematologic MalignanciesThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Ashley E. RoskoConsulting or Advisory Role: Association of Community Cancer Centers (ACCC), MedscapeTravel, Accommodations, Expenses: Jazz PharmaceuticalsRaul CordobaConsulting or Advisory Role: Takeda, Kyowa-Kirin, Kite/Gilead, Incyte, Janssen, Celgene/Bristol-Myers SquibbSpeakers' Bureau: Abbvie, AstraZeneca, RocheResearch Funding: PfizerTravel, Accommodations, Expenses: Janssen, Abbvie, RocheAndrew ArtzEmployment: Radiology PartnersStock and Other Ownership Interests: Radiology PartnersConsulting or Advisory Role: BiogenOpen Payments Link: https://openpaymentsdata.cms.gov/physician/331072Kah Poh LohConsulting or Advisory Role: Pfizer, Seattle GeneticsHeidi D. KlepinConsulting or Advisory Role: Genentech, PfizerPatents, Royalties, Other Intellectual Property: UpToDate contributorUncompensated Relationships: GenentechNo other potential conflicts of interest were reported.